Nordea Investment Management AB Has $1.71 Million Position in Natera, Inc. $NTRA

Nordea Investment Management AB lifted its position in Natera, Inc. (NASDAQ:NTRA) by 7.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,152 shares of the medical research company’s stock after acquiring an additional 687 shares during the period. Nordea Investment Management AB’s holdings in Natera were worth $1,711,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD raised its holdings in Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Nuveen LLC bought a new stake in shares of Natera in the 1st quarter valued at $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after buying an additional 732,156 shares during the period. JPMorgan Chase & Co. raised its stake in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after buying an additional 660,538 shares during the period. Finally, Ninety One UK Ltd lifted its holdings in Natera by 149.1% during the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after acquiring an additional 336,985 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.89, for a total transaction of $398,670.00. Following the sale, the insider directly owned 123,059 shares of the company’s stock, valued at approximately $16,353,310.51. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 14,083 shares of Natera stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the completion of the transaction, the chief executive officer directly owned 154,072 shares of the company’s stock, valued at approximately $24,651,520. This trade represents a 8.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 70,276 shares of company stock worth $10,794,948 over the last 90 days. Company insiders own 5.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on NTRA shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $200.00 price target on shares of Natera in a research report on Tuesday, October 14th. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Finally, Barclays restated an “overweight” rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $196.81.

Natera Stock Up 0.6%

Shares of NTRA stock opened at $188.02 on Thursday. The company’s fifty day simple moving average is $169.97 and its 200-day simple moving average is $159.37. The firm has a market cap of $25.81 billion, a PE ratio of -98.44 and a beta of 1.74. Natera, Inc. has a 12 month low of $117.27 and a 12 month high of $196.63.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period last year, the business posted ($0.30) EPS. The firm’s revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.